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Schistosomes are blood ﬂukes which cause schistosomiasis, a disease affecting
approximately 200 million people worldwide. Along with several other
important human parasites including trypanosomes and Plasmodium, schisto-
somes lack the de novo pathway for purine synthesis and depend exclusively
on the salvage pathway for their purine requirements, making the latter an
attractive target for drug development. Part of the pathway involves the
conversion of inosine (or guanosine) into hypoxanthine (or guanine) together
with ribose-1-phosphate (R1P) or vice versa. This inter-conversion is undertaken
by the enzyme purine nucleoside phosphorylase (PNP) which has been used as
the basis for the development of novel anti-malarials, conceptually validating
this approach. It has been suggested that, during the reverse reaction, R1P
binding to the enzyme would occur only as a consequence of conformational
changes induced by hypoxanthine, thus making a binary PNP–R1P complex
unlikely. Contradictory to this statement, a crystal structure of just such a binary
complex involving the Schistosoma mansoni enzyme has been successfully
obtained. The ligand shows an intricate hydrogen-bonding network in the
phosphate and ribose binding sites and adds a further chapter to our knowledge
which could be of value in the future development of selective inhibitors.
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1. Introduction
Schistosomiasis is the name of a severely debilitating disease
caused by parasites of the genus Schistosoma, among which
Schistosoma mansoni is the most prevalent species in the
world and is estimated to infect approximately 200 million
people (World Health Organization, 2005).The parasite shows
a complete dependence on preformed purines for its meta-
bolic needs owing to an absence of the enzymes which
comprise the ‘de novo’ pathway for purine biosynthesis.
Schistosome’s dependence on the purine salvage pathway for
providing essential purines may therefore represent a meta-
bolic ‘Achilles heel’ (Dovey et al., 1984; Senft & Crabtree,
1983; Senft et al., 1972).
One key component of this pathway is the enzyme purine
nucleoside phosphorylase (PNP), which catalyzes the rever-
sible phosphorolysis of the N-ribosidic bond of 6-oxopurine
deoxynucleosides and nucleosides yielding their correspon-
dent base and ribose-1-phosphate. Crystal structures of
several PNPs have been described which can be assigned to
two main categories: the low-molecular-mass homotrimeric
PNPs which bind to 6-oxopurines, and high-molecular-mass
homohexameric PNPs that accept either 6-oxo or 6-amino-
purine (such as adenosine) as substrates (Bzowska et al.,
2000). PNP has been considered as an attractive target for
drug development against several different parasitic infections
as well as against T-cell proliferative cancers (Madrid et al.,
2008; Rinaldo-Matthis et al., 2007; Schramm, 2004). Transition-
state analogues with Ki in the nM to pM range have been
developed for the proposed treatment of T-cell lymphoma
(Clinch et al., 2009; Rinaldo-Matthis et al., 2007; Schramm,
2004; Chen & Advani, 2008) and several ground-state purine
analogues have been assayed for their Schistosomicidal
activity (el Kouni, 1991; el Kouni et al., 1987; Dovey et al.,
1985).
An important step to improve the potency and selectivity
of current inhibitors of PNP which might be useful against
schistosomiasis is a more complete structural characterization
of the enzyme’s catalytic mechanism. For instance, although
over 100 PNP structures from 13 different organisms have
been described to date, none of them describe the crystal-
lographic structure of PNP as a binary complex with ribose-1-
phosphate (R1P), one of the products of the phosphorolysis
reaction. Currently, only an approximate description of this
stage in catalysis is available from a ternary complex between
bovine PNP, hypoxanthine and R1P [Protein Data Bank
(PDB) code 1a9t] (Mao et al., 1998). Following unsuccessful
attempts to obtain a complex of bovine PNP with R1P, these
PDB Reference: 3fb1.authors hypothesized that R1P binding would occur as a
consequence of conformational changes induced by hypox-
anthine, thus making a PNP–R1P complex unlikely.
A second mechanistically important point that requires
further elucidation is the importance of the conformational
change described as the ‘gate movement’ which occurs upon
substrate binding. This movement requires residues 257–265
in both human and bovine PNPs to shift from a coil to an -
helical conformation (Canduri et al., 2004; Mao et al., 1998).
On the other hand, previous crystallographic studies of
SmPNP have shown that the equivalent region (residues 259–
267) in subunits A and C is already helical even in the absence
of bound ligand (Pereira et al., 2005). In subunit B this region
is frequently disordered and only assumes an -helical
conformation in the presence of bound nucleoside while
presenting an alternative extended structure in the complex
with adenine (3e9r) (Pereira et al., 2010). However, such
analyses are complicated by the potential effects of crystal
packing forces.
Aiming at shedding some further light on these questions
we report for the ﬁrst time the crystal structure of a binary
complex between PNP and R1P alone. We make comparisons
with other known complexes which serve to illustrate the
progressive structural rearrangements of the low-molecular-
weight PNPs required for binding and catalysis.
2. Materials and methods
2.1. Crystallization, soaking and X-ray data collection
SmPNP was expressed, puriﬁed and crystallized as
previously described (Pereira et al., 2003 2005). The soaking
solution consisted of 5 mM R1P, 20% PEG 1500, 15 mM
sodium acetate buffer pH 4.9 or 5.0 (at the pH of crystal
growth) and 20% glycerol. The crystals were maintained in
this solution for up to 48 h.
X-ray diffraction data were collected at 100 K on beamline
MX1 of the LNLS (Campinas, Brazil) using an X-ray wave-
length of 1.43 A ˚ . The crystals of the complex SmPNP–R1P
diffract up to 2.0 A ˚ resolution. The data were indexed and
integrated using the program MOSFLM (Leslie, 1999) and
scaled using the program SCALA from the CCP4 suite
(Collaborative Computational Project, Number 4, 1994).
2.2. Structure solution and refinement
The SmPNP–R1P complex was solved by molecular repla-
cement employing MOLREP (Vagin & Teplyakov, 2000) and
using native SmPNP (1td1) as a search model (Pereira et al.,
2005). The reﬁnement was carried out using Phenix (Adams et
al., 2002) together with Coot (Emsley & Cowtan, 2004) for
model building into a-weighted 2Fo   Fc and Fo   Fc electron
density maps.The compounds were automatically placed using
the ‘Find Ligand’ routine of Coot; the water molecules were
identiﬁed and positioned using both Coot and Phenix.
Both R and Rfree were monitored in order to evaluate the
validity of the reﬁnement protocol and the stereochemical
quality of the model was calculated using Procheck
(Laskowski et al., 1993). The coordinates and structure factors
have been deposited in the PDB under the code 3fb1.
3. Results
3.1. Overall structure description
The asymmetric unit of the structure of SmPNP in complex
with R1P (SmPNP–R1P) contains the full PNP trimer (6347
protein atoms) along with 368 water molecules, three mole-
cules of R1P and three molecules of acetate. The ﬁnal R and
Rfree values as well as other statistical parameters from the
data collection and model reﬁnement are listed in Table 1. All
ligands, including three R1P molecules, were readily posi-
tioned in the Fo   Fc electron density map (Fig. 1) whilst
residues for which there was little or no interpretable density
were removed from the ﬁnal structure (subunit A: residues 1–3
and 63–65; subunit B: 1–3 and 254–266; subunit C: 1–2).
3.2. Active site description
We describe here the ﬁrst binary complex between PNP and
the reaction product R1P. Previously, Mao and collaborators
have described two ternary complexes of the bovine enzyme
involving the R1P product, one in the presence of 9-deaza-
hypoxanthine and the other in the presence of hypoxanthine
(Mao et al., 1998). These authors demonstrated that the bovine
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Table 1
Full data collection and reﬁnement statistics for SmPNP–R1P.
The numerals in parentheses are from the highest-resolution shell.
Data collection
Space group P212121
Cell dimensions a, b, c (A ˚ ) 48.92, 117.55, 29.23
Detector MarCCD 165
X-ray source LNLS D03B-MX1
Wavelength (A ˚ ) 1.432
Resolution range (A ˚ ) 129.67–2.0 (2.11–2.0)
Redundancy 4.5 (4.7)
Rmeas (%)† 7.5 (55.3)
Completeness (%) 95.1 (86.7)
Total reﬂections 341663 (15830)
Unique reﬂections 48547 (6312)
I/(I) 14.5 (2.0)
Reﬁnement parameters
Reﬂections used for reﬁnement 45735
R (%)‡ 17.7
Rfree (%)‡ 23.4
Overall averaged B-factor (A ˚ 2) 35.70
Ligand averaged B-factor (A ˚ 2) 36.98
No. of protein atoms 6347
No. of water molecules 368
No. of ligand atoms 54
Ramachandran plot
Most favoured region (%) 90.8
Residues in disallowed regions (%) 0.4
R.m.s. bond lengths (A ˚ ) 0.014
R.m.s. bond angles ( ) 1.223
† Rmerge = hkli|Ii(hkl)  h I(hkl)i|/hkliIi(hkl), where Ii(hkl) is the observed intensity
of the measured reﬂection and hI(hkl)i is the averaged intensity over equivalent
reﬂections from different measurements. ‡ R is the conventional crystallographic R-
factor, ||Fobs|   |Fcalc||/|Fobs|, where Fobs and Fcalc are the observed and calculated
structure factors, respectively. 5% of the reﬂections that were excluded from the
reﬁnement were used in the Rfree calculation.PNP crystals are catalytically active under the crystallization
conditions used and that the enzyme can bind R1P in the
presence of hypoxanthine. However, they were unable to
obtain a complex of bovine PNP with R1P alone, even after
exhaustive soaking experiments including up to 4 mM
concentrations of the ligand. The authors concluded that R1P
does not bind alone to the PNP active site but rather that this
is a result of conformational changes induced by hypoxanthine
binding which leads to an increased afﬁnity for R1P.
Contrary to this hypothesis, we have been able to obtain the
elusive binary complex of SmPNP with R1P (Fig. 1). It is
interesting to speculate as to why we have been successful
where previous attempts failed. One possibility is the time
used during the soaking experiment, which was much longer
than that reported previously (48 h compared with a
maximum of 2 h used for bovine PNP). In the case of SmPNP,
experiments in which shorter soaking times were used proved
to be unsuccessful. Secondly it is worth pointing out that the
PNP binding site is known to be extremely ﬂexible and often
presents differences even between subunits of a given crystal
form. This would seem to suggest great sensitivity to crystal
environment and packing forces which are known to inﬂuence
the success of soaking experiments.
The ligand presents an intricate hydrogen-bonding network
involving either ten direct and four
water-mediated hydrogen bonds
(subunit A) or nine direct and ﬁve
water-mediated hydrogen bonds (sub-
units B and C). These interactions are
limited to the well deﬁned phosphate
and ribose binding sites which are lined
by residues S35, R86, H88, Y90, A118,
Y202, M221, S222 and H259. Overall,
the structures of the three monomers
are highly conserved, not deviating
more than  0.2 A ˚ RMSD from one
another after C superposition.
The base binding site is occupied by
one acetate molecule which interacts
with E203 as described in previous
SmPNP structures (Pereira et al., 2005).
Overall the phosphate and ribose
binding sites of all three subunits are
very similar, but two exceptions are
worthy of mention. Firstly the loop from
residue 250 to 266 in the B subunit
cannot be seen in the 2Fo   Fc electron
density map, as is frequently the case in
other SmPNP structures. This suggests
that the binding of R1P is not sufﬁcient
in itself to cause the loop rearrangement
observed in complexes with the
nucleosides inosine and adenosine.
Even in subunits A and C, where the
loop is well ordered, signiﬁcant differ-
ences compared with the SmPNP–
inosine structure can be seen. This is
most notable for the interaction between O50 of the ribose and
H259 N1, which is weaker in the SmPNP–R1P complex (3.4 A ˚
and 3.07 A ˚ in subunits A and C, respectively, compared with
2.73 A ˚ and 2.62 A ˚ in the SmPNP–inosine complex).
The second difference involves the phosphate binding loop
(residues 33 to 37). In previously determined structures of
SmPNP with inosine (3faz), adenosine (3f8w) and hypox-
anthine (3fqn), in which the phosphate binding site is occupied
by sulfate, this loop presents two different conformations in
the three subunits. The SmPNP–R1P complex is the ﬁrst
structure in which we observe a unique conformation for this
loop suggesting that the anionic moiety may need to be
covalently bound to the ribose in order to fully favour all
interactions made by this loop. These include those made
simultaneously by Ser35 which include hydrogen bonds
between O and R1P O10and O40 and the main chain nitrogen
with O3P (Fig. 2). This is supported by the observation of
similar interactions made in the ternary complex of bovine
PNP with R1P and hypoxanthine (1a9t) (Mao et al., 1998). Our
attempts to obtain a similar ternary complex in the case of
SmPNP by soaking were unsuccessful, SmPNP–hypoxanthine
complexes being obtained instead.
Fig. 3 shows simultaneously complexes between SmPNP
and hypoxanthine/SO4, inosine/SO4 and R1P. The most
diffraction structural biology
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Figure 2
Stereo image showing the interactions made by ribose-1-phosphate in subunit A of SmPNP. The
conformation of the phosphate binding loop, centred on residue S35, allows the formation of
hydrogen bonds between O of S35 and O10 and O40 of R1P as well as the main chain NH with O3P.
Figure 1
Stereo image of an omit map contoured at 3 for ribose-1-phosphate in the active site of SmPNP
(A subunit).notable difference seems to be the orientation of the ribose in
the latter two complexes. This would seem to emphasize the
comment made above that the connectivity between the
phosphate and ribose is essential for correctly closing the
phosphate binding loop. Together with the many different
complexes described to date from several different species, the
structure we present here therefore serves to complete the
overall picture of ﬂexibility within the PNP active site.
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Figure 3
Superposition of the complexes between SmPNP and inosine/SO4 (green), hypoxanthine/SO4
(yellow) and ribose-1-phosphate (white). Protein residues are shown only for the SmPNP–R1P
structure.